Free Trial

Amicus Therapeutics (FOLD) Stock Forecast & Price Target

$10.32
-0.06 (-0.58%)
(As of 10:43 AM ET)

Amicus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 8 Wall Street analysts who have issued ratings for Amicus Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a hold rating, and 7 have given a buy rating for FOLD.

Consensus Price Target

$17.57
70.27% Upside
High Forecast$22.00
Average Forecast$17.57
Low Forecast$13.00

According to the 8 analysts' twelve-month price targets for Amicus Therapeutics, the average price target is $17.57. The highest price target for FOLD is $22.00, while the lowest price target for FOLD is $13.00. The average price target represents a forecasted upside of 70.27% from the current price of $10.32.

TypeCurrent Forecast
7/23/23 to 7/22/24
1 Month Ago
6/23/23 to 6/22/24
3 Months Ago
4/24/23 to 4/23/24
1 Year Ago
7/23/22 to 7/23/23
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.57$17.57$20.00$15.20
Forecasted Upside70.27% Upside73.75% Upside62.53% Upside26.08% Upside
Get Amicus Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

FOLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

FOLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Amicus Therapeutics Stock vs. The Competition

TypeAmicus TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside69.28% Upside2,980.97% Upside10.08% Upside
News Sentiment RatingVery Positive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/30/2024Wells Fargo & Company
3 of 5 stars
 Initiated CoverageOverweight$18.00+92.31%
5/14/2024Guggenheim
3 of 5 stars
D. Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$13.00+43.81%
5/10/2024UBS Group
4 of 5 stars
 Lower TargetBuy ➝ Buy$20.00 ➝ $19.00+105.85%
5/10/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$20.00 ➝ $19.00+106.52%
5/10/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
5/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$14.00 ➝ $13.00+37.13%
3/18/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$21.00 ➝ $19.00+62.81%
2/29/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$22.00+71.74%
3/2/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$10.00 ➝ $11.00-18.82%
1/18/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$14.00 ➝ $16.00+28.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:07 AM ET.

FOLD Forecast - Frequently Asked Questions

What is Amicus Therapeutics' forecast for 2024?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Amicus Therapeutics is $17.57, with a high forecast of $22.00 and a low forecast of $13.00.

Should I buy or sell Amicus Therapeutics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There is currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares.

Does Amicus Therapeutics's stock price have much upside?

According to analysts, Amicus Therapeutics's stock has a predicted upside of 73.75% based on their 12-month stock forecasts.

Has Amicus Therapeutics been upgraded by Wall Street analysts recently?

Over the previous 90 days, Amicus Therapeutics's stock had 1 upgrade by analysts.

What analysts cover Amicus Therapeutics?

Amicus Therapeutics has been rated by research analysts at Bank of America, Guggenheim, Morgan Stanley, Needham & Company LLC, UBS Group, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Amicus Therapeutics more than its competitors?

Analysts like Amicus Therapeutics more than other "medical" companies. The consensus rating score for Amicus Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.72. Learn more on how FOLD compares to other companies.


This page (NASDAQ:FOLD) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners